MedTrace Logo

Phase I BLASST-3 Trial

NCT04972253 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2022-08-10

No results posted yet for this study

Summary

The aim of this research is to see whether using a drug that blocks a protein called FGFR (fibroblast growth factor receptor) prior to surgery is safe and effective in patients with bladder cancer that have mutations in FGFR3 or FGFR2 and who cannot receive chemotherapy with cisplatin prior to surgery

The name of the study drug involved in this study is:

\- Infigratinib

Conditions

  • Bladder Transitional Cell Carcinoma
  • Bladder Cancer
  • Fibroblast Growth Factor Receptor

Interventions

DRUG

Infigratinib

Oral, dosage per protocol

Sponsors & Collaborators

  • QED Therapeutics, Inc., a Bridgebio company

    collaborator INDUSTRY

  • Guru P. Sonpavde

    lead OTHER

Principal Investigators

  • Guru Sonpavde, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-23
Primary Completion
2022-12-31
Completion
2023-12-31
FDA Drug
Yes

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04972253 on ClinicalTrials.gov